MMR vaccine

Global Paediatric Vaccine Markets 2020-2025 - Rising Number of Collaborations, Expansions, and Mergers

Retrieved on: 
Wednesday, January 6, 2021
Medical specialties, Clinical medicine, Medicine, Vaccination, Vaccines, Virology, Mumps, Vaccine, MMR vaccine, Polio, Vaccination schedule, Vaccine hesitancy

These vaccines include the DTP vaccine, MMR vaccine, polio vaccine, and meningococcal vaccine, etc.

Key Points: 
  • These vaccines include the DTP vaccine, MMR vaccine, polio vaccine, and meningococcal vaccine, etc.
  • Certain factors, such as the rising number of chronic diseases across the globe along with the global initiatives taken towards vaccine production for rare diseases, have been major drivers of growth for the pediatric market.
  • By Vaccine Type, the Monovalent Vaccine is estimated to account for the fastest-growing segment during the forecast period.
  • By Application, The Infectious Diseases Segment holds the largest share due to rising global awareness about immunization against infectious diseases that cause death.

New Peer-Reviewed Study: MMR Vaccine Protection Against COVID-19 Studied by World Organization

Retrieved on: 
Friday, November 20, 2020
Medical specialties, Clinical medicine, Vaccination, Vaccines, Measles, Pediatrics, Vaccine-preventable diseases, MMR vaccine, Vaccine, Mumps, Immunoglobulin G, Rubella

ATLANTA, Nov. 20, 2020 /PRNewswire/ --In " Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients " researchers provide further proof to the theory that the measles-mumps-rubella (MMR) vaccine provides protection against COVID-19.

Key Points: 
  • ATLANTA, Nov. 20, 2020 /PRNewswire/ --In " Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients " researchers provide further proof to the theory that the measles-mumps-rubella (MMR) vaccine provides protection against COVID-19.
  • Researchers found that mumps IgG titers are inversely correlated with severity in recovered COVID-19 patients previously vaccinated with MMR II.
  • "The MMR II vaccine is considered a safe vaccine with very few side effects.
  • "This adds to other associations demonstrating that the MMR vaccine may be protective against COVID-19.

WebMD Poll: More than half will get Covid-19 vaccine in first year, 42% in first six months

Retrieved on: 
Wednesday, September 2, 2020
Drugs, RTT, Medical specialties, Vaccination, Vaccines, Vaccine, MMR vaccine, Influenza vaccine, Rubella vaccine, Mumps, HPV vaccine, Vaccination policy

Fewer than one-third say they will get the vaccine in the first three months, which is consistent in both polls.

Key Points: 
  • Fewer than one-third say they will get the vaccine in the first three months, which is consistent in both polls.
  • In the new poll, about 12% said they will not get a vaccine at all, and the rest remain unsure.
  • Vaccine efficacy rates range from about 40% to 60% for the seasonal flu vaccine, to 97% for the measles, mumps and rubella vaccine, according to CDC data .
  • "Understanding how well the vaccine works could be a hurdle for patients," said John Whyte, MD, chief medical officer of WebMD.

COVID-19 / MMR Vaccine Preprint Available: World Organization Has Completed Its Research

Retrieved on: 
Thursday, May 14, 2020
Drugs, Viruses, Viral diseases, Vaccines, Measles, MMR vaccine controversy, Mumps, RTT, MMR vaccine, Vaccination schedule, Vaccine, Severe acute respiratory syndrome-related coronavirus

ATLANTA, May 14, 2020 (GLOBE NEWSWIRE) -- The report MMR Vaccine Appears to Confer Strong Protection from COVID-19: Few Deaths from SARS-CoV-2 in Highly Vaccinated Populations written by principal investigator Jeff Gold is now available as a preprint on ResearchGate.

Key Points: 
  • ATLANTA, May 14, 2020 (GLOBE NEWSWIRE) -- The report MMR Vaccine Appears to Confer Strong Protection from COVID-19: Few Deaths from SARS-CoV-2 in Highly Vaccinated Populations written by principal investigator Jeff Gold is now available as a preprint on ResearchGate.
  • In preparing this report, Gold evaluated epidemiological data about MMR vaccine programs in dozens of countries, with each correlation verified by co-investigators William H. Baumgartl, MD, MSME, and Larry P. Tilley, Diplomate, ACVIM.
  • Golds initial version of this report was first published on the World Organization website on March 29, 2020.
  • World Organization is a 501c3 nonprofit charity based in Atlanta, Georgia.

COVID-19 and Kawasaki Disease: Low MMR Vaccine Responsiveness Could Be Affecting Children According to World Organization

Retrieved on: 
Thursday, May 14, 2020
Medical specialties, RTT, Medicine, Drugs, Vaccines, Pediatrics, Vaccine-preventable diseases, Rubella, MMR vaccine, Rubella vaccine, Vaccine, Measles

Some young children with a rare condition known as Kawasaki disease are, however, getting severe COVID-19 complications which could relate to a relationship between MMR vaccines and COVID-19.

Key Points: 
  • Some young children with a rare condition known as Kawasaki disease are, however, getting severe COVID-19 complications which could relate to a relationship between MMR vaccines and COVID-19.
  • A tremendous amount of data points to the conclusion that the rubella component of MMR vaccines is what protects most children from COVID-19.
  • The 1999 study by Kuijpers et al Kawasaki Disease: A Maturational Defect in Immune Responsiveness concluded that an incomplete responsiveness to measles-mumps-rubella vaccination was seen in patients with Kawasaki disease.
  • It follows that to the extent MMR vaccines are guarding children from COVID-19, those who have Kawasaki disease could be left largely unprotected.

MMR Vaccine May Protect People Over 50 from COVID-19 According to World Organization

Retrieved on: 
Wednesday, April 29, 2020
Medical specialties, Medicine, Drugs, RTT, Vaccines, Pediatrics, Vaccine-preventable diseases, Rubella, MMR vaccine, Vaccine, Vaccination, Measles

ATLANTA, April 29, 2020 (GLOBE NEWSWIRE) -- Epidemiological data revealed in an MMR vaccines and COVID-19 investigation by World Organization suggests it is possible that widely deployed MMR and other measles-rubella containing vaccines protect older adults as well as the young from COVID-19.

Key Points: 
  • ATLANTA, April 29, 2020 (GLOBE NEWSWIRE) -- Epidemiological data revealed in an MMR vaccines and COVID-19 investigation by World Organization suggests it is possible that widely deployed MMR and other measles-rubella containing vaccines protect older adults as well as the young from COVID-19.
  • Hong Kong is a prime example of a region which has extended its MMR vaccination campaigns to include many adults.
  • World Organizations conclusion that MMR vaccines may have a protective effect has been corroborated by a recent unreviewed study be neuroscientists at the University of Cambridge indicating the rubella component of MMR has a protective effect against COVID-19.
  • World Organization is a 501c3 nonprofit charity based in Atlanta, Georgia.

Possible Connection of MMR Vaccine to Mild COVID-19 Cases Studied by Dr. Larry P. Tilley, World Organization Advisory Board Member

Retrieved on: 
Tuesday, April 28, 2020
Medical specialties, Drugs, RTT, Medicine, Vaccines, Pediatrics, Vaccine-preventable diseases, MMR vaccine, Rubella, Vaccine, Measles, Vaccination

ATLANTA, April 28, 2020 (GLOBE NEWSWIRE) -- World Organization Advisory Board Member Dr. Larry Tilley is investigating a possible link between MMR vaccines and COVID-19 .

Key Points: 
  • ATLANTA, April 28, 2020 (GLOBE NEWSWIRE) -- World Organization Advisory Board Member Dr. Larry Tilley is investigating a possible link between MMR vaccines and COVID-19 .
  • Tilleys investigation began on March 25, 2020 when he discovered epidemiological data suggesting a possible protective effect from common measles-rubella containing vaccines like MMR.
  • Epidemiological data from country after country seems to suggest expanded measles-rubella containing vaccination programs correlate with lower morbidity from COVID-19, said Tilley.
  • A possible biological mechanism for the protective effect of measles-rubella vaccines was described in an unreviewed study published recently by scientists at University of Cambridge.

Vaxxas Awarded US$5 million [AU$7.5 million] Grant for Clinical Study of Measles and Rubella Vaccination using Vaxxas’ High Density Micro-Array Patch

Retrieved on: 
Tuesday, March 17, 2020
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Medical specialties, Medicine, Infectious diseases, RTT, Vaccine-preventable diseases, Pediatrics, Vaccine, Measles, Rubella, Vaccination, MMR vaccine

Vaxxas, a biotechnology company commercializing a novel vaccination platform, today announced that it has received a US$5 million [AU$7.5 million] grant to conduct initial human clinical studies using Vaxxas High Density Microneedle Array Patch (HD-MAP) for measles and rubella vaccination.

Key Points: 
  • Vaxxas, a biotechnology company commercializing a novel vaccination platform, today announced that it has received a US$5 million [AU$7.5 million] grant to conduct initial human clinical studies using Vaxxas High Density Microneedle Array Patch (HD-MAP) for measles and rubella vaccination.
  • The new funding will be used for IND-enabling studies and a first-in-human clinical study for measles and rubella vaccination using Vaxxas advanced HD-MAP platform.
  • The measles and rubella vaccine formulation used to coat the HD-MAP has been engineered to be stable at higher temperatures than required for needle/syringe vaccination.
  • In 2018 and 2019, inadequate measles vaccine coverage resulted in a massive global resurgence of preventable measles cases and deaths.

Physicians for Informed Consent Educates Parents About the Risk of Seizures and Epilepsy from the MMR Vaccine

Retrieved on: 
Tuesday, November 12, 2019
Drugs, Medicine, Medical specialties, RTT, Measles, Vaccines, MMR vaccine controversy, Mumps, MMR vaccine, Vaccine, Vaccination, MMRV vaccine

Seizures from the MMR vaccine occur in about 1 in 640 children within two weeks of receiving the first dose of the MMR vaccine.

Key Points: 
  • Seizures from the MMR vaccine occur in about 1 in 640 children within two weeks of receiving the first dose of the MMR vaccine.
  • This amounts to approximately 5,700 cases of MMR-vaccine seizures annually in the U.S., and a significant portion of MMR-vaccine seizures cause permanent harm, as 5% of febrile seizures result in epilepsy.
  • Families must objectively weigh the risks of measles vs. the risks of the MMR vaccine, to make informed, evidence-based vaccination decisions."
  • Physicians for Informed Consent is a 501(c)(3) educational nonprofit organization focused on science and statistics.

Physicians for Informed Consent: CDC Data Shows Immunity from the MMR Vaccine Wanes Over Time

Retrieved on: 
Friday, August 23, 2019
Drugs, Medicine, Medical specialties, RTT, Measles, Vaccines, MMR vaccine controversy, Mumps, Vaccine, MMR vaccine, MMR vaccine and autism, Vaccination schedule

Designed to help doctors and the public evaluate the effectiveness of the MMR vaccine, the document answers a common question parents ask when carefully considering the MMR vaccine for their children: "For how long will the MMR vaccine protect my child?"

Key Points: 
  • Designed to help doctors and the public evaluate the effectiveness of the MMR vaccine, the document answers a common question parents ask when carefully considering the MMR vaccine for their children: "For how long will the MMR vaccine protect my child?"
  • In 2007, the Centers for Disease Control and Prevention (CDC) conducted a study on waning immunity after two doses of the MMR vaccine.
  • [6] "Waning MMR vaccine immunity is an important factor for physicians and parents to consider when evaluating the risks of measles infection vs. the risks and limitations of the MMR vaccine," said Dr. Shira Miller, PIC founder and president.
  • To read the document, "Waning Immunity and the MMR Vaccine: Nearly 50 Percent of Vaccinated Schoolchildren Can Become Infected with Measles," please visit physiciansforinformedconsent.org/mmr-waning-immunity .